Basics Syndax Pharmaceuticals, Inc. Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. IPO Date: March 3, 2016 Sector: Healthcare Industry: Biotech Market Cap: $792.5M Activated in VL: True Average Daily Range Avg Daily Range: $0.40 | 2.83% Avg Daily Range (30 D): $0.27 | 2.83% Avg Daily Range (90 D): $0.38 | 3.46% Institutional Daily Volume Avg Daily Volume: .54M Avg Daily Volume (30 D): 1.39M Avg Daily Volume (90 D): 1.65M Trade Size Avg Trade Size (Sh.): 87 Avg Trade Size (Sh.) (30 D): 83 Avg Trade Size (Sh.) (90 D): 85 Institutional Trades Total Inst.Trades: 2,942 Avg Inst. Trade: $2.32M Avg Inst. Trade (30 D): $2.52M Avg Inst. Trade (90 D): $2.41M Avg Inst. Trade Volume: .13M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.84M Avg Closing Trade (30 D): $3.16M Avg Closing Trade (90 D): $3.65M Avg Closing Volume: 159.45K     News May 29, 2025 @ 11:00 AM Syndax Announces Participation in June Investor Co... Source: N/A Mar 3, 2025 @ 12:01 PM Syndax Reports Fourth Quarter and Full Year 2024 F... Source: Syndax Pharmaceuticals Feb 24, 2025 @ 12:00 PM Syndax to Announce Fourth Quarter and Full Year 20... Source: N/A Feb 10, 2025 @ 10:42 PM Kuehn Law Encourages Investors of Syndax Pharmaceu... Source: N/A Jan 28, 2025 @ 6:00 PM Pulmonary Fibrosis Clinical Trial Pipeline Appears... Source: Delveinsight Financials   TTM Q1 2025 Q3 2024 Basic EPS $-.98 $-.98 Diluted EPS $-.98 $-.98 Revenue $ $ 20.04M $ 12.5M Gross Profit $ $ $ Net Income / Loss $ $ -84.85M $ -84.13M Operating Income / Loss $ $ -83.76M $ -89.58M Cost of Revenue $ $ $ Net Cash Flow $ $ -.09M $ 27.62M PE Ratio